golden opportunity to add to position today and any day this stock trades below $32 a share until earnings. Then company will likely provide some forward guidance and IMHO look out as this stock will roar. $50-$70 by this time next year if not acquired in the interim.
800 m sales x 6= 4.8 b : 68 m shares = $ 70. that would be fair value. if you think $ 25 is fair, then you see no future. i believe personalized medicine has only started. mygn has been screwed by former management, it only can get better .......
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.7 In other words, the correlation coefficient of the other stock
China Education Resources CHN V
Nice upward movement yesterday longs! get shorty....
New York Times 6/8/17 has an article about the evidence supporting approval of immunotherapy to treat cancer patients with the genetic defects MSI-H and dMMR. Familial MSI-H defect is Lynch syndrome, which MyRisk tests for. Beyond that, I know nothing of interest.
Do you think this thing is done selling? Showing us a buy signal now on MYGN? google awesome.stocks - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
buying AXSM at $4 is like buying JAZZ at $1 a few years ago now trading at $151 (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
nope , nothing mygn can announce at this point will impact the stock. they dont have a clue how to grow the company.
The last time MYGN did something like this it blew up. Not sure how awesome.stocks finds all these incredible trade ideas but im happy.
DRE Conversations | Duke Realty Corporation Common - Yahoo Finance
Welcome to largest financial internet forum where people can hold conversations related to stock trading and investing in equities. You can share your opinion and views on various topics from exciting world of finance.
The Prolaris Medicare reimbursement expansion covers exactly the population most likely to be seeking "one more piece of information" in choosing between watchful waiting or more aggressive treatment.
Is it time to make a move on MYGN? have you guys heard of awe-someSTOCKS. i started receiving their allerts and so far i am happy.
China Education Resources CHN V
A week ago, I called the $23 pps. MYGN is one of the most heavily shorted stocks on the stock exchange. Major short squeeze could push this stock to $28 in no time!
they beat savagely low expectations. stock is clear to trade at $22 or $23. very impressive, not. they dont really have much of a plan do they? hence the flat quarter in q2. in a down market, it could re-test $15.
Just listened to the CC. Pretty much what was needed, and what would be expected at this stage of playing out a "dumpster year." Didn't notice much about growth initiatives that are definitely there (esp kit-based tests). Lots of fiddly accounting changes. I now expect a pretty good August call with a forecast that sounds slightly optimistic. The plan, of course, is that they hope to beat the optimistic-sounding forecast by ever-increasing amounts. That's what Myriad used to do. and 15+ months after last August's CC, analysts may easily be receptive. I'd like to have a Shareholders' Day sometime in the next year, but nobody's listening.
My guess is that MYGN is due for a pullback in the short-run. I started receiving notifications from aawesomestocks the other week and so far they have presented interesting new trade ideas.
It appears that the PARP inhibitor Rubraca (available now under acccelerated approval) will have a need for BRCA testing on label. The manufacturer is specifying Incyte's test for germ-line mutation, and the drug has been added to Myriad's FDA filings for somatic BRCA mutation testing.
It's complicated, but it's good news.
With earnings approaching: I expect meet, but not beat forecasts. Stable on hereditary cancer. Insurance companies continuing to resist Prolaris, for whatever insurance company reasons. Great results would be pointless, because last August still isn't forgiven. It'd be nice to get a little more color on timing of kit-based test timeline, and maybe a teaser on companion diagnostics unrelated to DNA-break repair. General non-event nature of RA biosimilars introduction (and delay, possibly a very long one, on Olumiant) leaves the case for Vectra stronger than anticipated. Non-repeal of Obamacare generally optimistic for Genesight. But again, management announced that they're not pushing for a breakthrough quarter, and with the analysts annoyed, there wouldn't be any point.
There seems to be enough bearishness around to make a so-so-quarter somewhat positive to the stock price, so next Q will probably average above $20...just not much more than that.
And for That Guy--Myriad management did everything remotely sensible that you have ever suggested, usually at least a year before you suggested it. concerning less-sensible ideas, I recall well when Quaker Oats used Wilford Brimley as a spokeman, and got burned eventually by his support for cockfighting, among other problems.
today's news very good as it identifies MYGN as best in class companion diagnostic test